Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Radiotherapy + Zotiraciclib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Radiotherapy | ||||
| Zotiraciclib | SB1317|TG02 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK5 Inhibitor 8 CDK7 Inhibitor 16 CDK9 Inhibitor 21 FLT3 Inhibitor 69 JAK2 Inhibitor 19 | Zotiraciclib (TG02) is a pyrimidine-based molecule that inhibits CDK1, CDK2, CDK3, CDK5, CDK7, CDK9, JAK2, and FLT3, which results in growth inhibition in tumor cells (PMID: 21860433). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03224104 | Phase I | Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib | Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) | Completed | NLD | FRA | DEU | CHE | AUT | 0 |